IP Library Granted Patent US 11,453,903
Granted Patent B2
US 11,453,903 · App. 16/307,378 · Granted Sep 27, 2022

Production of activated clostridial neurotoxins

Inventors: Laura Lovelock (Abingdon, GB); Daniel Kwan (Abingdon, GB); Peter Daniel Horrocks (Abingdon, GB); Malgorzata Field (Abingdon, GB); Philip Marks (Abingdon, GB)
Assignee: IPSEN BIOPHARM LIMITED
C12P21/06A61K38/4893C12N9/52C12Y304/24069C07K14/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,453,903
App. No.
16/307,378
Granted
Sep 27, 2022
Kind
B2
Abstract

Method of producing an activated clostridial neurotoxin. Composition comprising an activated clostridial neurotoxin. Method of treatment using a composition comprising an activated clostridial neurotoxin.

Claims (14)

1. A method for producing a composition comprising an activated clostridial neurotoxin and less than 10% A single-chain or truncated clostridial neurotoxin, the method comprising:

contacting a single-chain clostridial neurotoxin comprising a BoNT/E activation loop with trypsin at a concentration of 0.5 to 3 μg per mg of clostridial neurotoxin and a pH between 6 and 7 for a duration of 15 to 25 hours to convert the single-chain clostridial neurotoxin into di-chain clostridial neurotoxin; and

contacting the di-chain clostridial neurotoxin with a mixed mode chromatography resin.

2. The method of claim 1 , wherein the trypsin comprises an amino acid sequence that has at least 90% identity with SEQ ID NO: 1.

3. The method of claim 2 , wherein the trypsin is obtained from bovine pancreas or a recombinant bovine trypsin.

4. The method of claim 1 , wherein the single-chain clostridial neurotoxin is obtained by expressing a gene encoding the single-chain clostridial neurotoxin in a heterologous host cell.

5. The method of claim 2 , wherein the step of contacting the single-chain clostridial neurotoxin with the trypsin is performed at a pH of approximately 6.5.

6. The method of claim 1 , wherein the single-chain clostridial neurotoxin is obtained by expressing a gene encoding the single-chain clostridial neurotoxin in E. coli.

7. The method of claim 1 , wherein the mixed mode chromatography resin is a ceramic hydroxyapatite type II resin.

8. The method of claim 1 , wherein the clostridial neurotoxin is a chimeric clostridial neurotoxin or a re-targeted clostridial neurotoxin.

9. The method of claim 1 , wherein the clostridial neurotoxin is a mutated clostridial neurotoxin, a chimeric clostridial neurotoxin, or a re-targeted clostridial neurotoxin.

10. The method of claim 1 , wherein the composition comprises less than 5% single-chain or truncated clostridial neurotoxin.

11. The method of claim 1 , wherein the composition comprises less than 1% single-chain or truncated clostridial neurotoxin.

12. The method of claim 1 , wherein the composition comprises less than 0.1% single-chain or truncated clostridial neurotoxin.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: HORROCKS, PETER DANIEL
To: SYNTAXIN LIMITED
Reel/Frame 055531/0746 →
CHANGE OF NAME Recorded Mar 9, 2021
From: SYNTAXIN LIMITED
To: IPSEN BIOINNOVATION LIMITED
Reel/Frame 055531/0937 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2021
From: IPSEN BIOINNOVATION LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 055532/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2019
From: LOVELOCK, LAURA; KWAN, DANIEL; FIELD, MALGORZATA; MARKS, PHILIP
To: IPSEN BIOPHARM LIMITED
Reel/Frame 049843/0287 →
Priority Claims (1)
EP 16177651 · Jul 1, 2016 · regional
Continuity (1)
Related Publication 20190161783A1 · May 30, 2019